Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Urbanski LM, Leclair N, Anczuków O.

Wiley Interdiscip Rev RNA. 2018 Jul;9(4):e1476. doi: 10.1002/wrna.1476. Epub 2018 Apr 25. Review.

2.

Splicing-factor alterations in cancers.

Anczuków O, Krainer AR.

RNA. 2016 Sep;22(9):1285-301. doi: 10.1261/rna.057919.116. Review.

3.

The spliceosome, a potential Achilles heel of MYC-driven tumors.

Anczuków O, Krainer AR.

Genome Med. 2015 Oct 22;7:107. doi: 10.1186/s13073-015-0234-3.

4.

SRSF1-Regulated Alternative Splicing in Breast Cancer.

Anczuków O, Akerman M, Cléry A, Wu J, Shen C, Shirole NH, Raimer A, Sun S, Jensen MA, Hua Y, Allain FH, Krainer AR.

Mol Cell. 2015 Oct 1;60(1):105-17. doi: 10.1016/j.molcel.2015.09.005.

5.

Isolated pseudo-RNA-recognition motifs of SR proteins can regulate splicing using a noncanonical mode of RNA recognition.

Cléry A, Sinha R, Anczuków O, Corrionero A, Moursy A, Daubner GM, Valcárcel J, Krainer AR, Allain FH.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):E2802-11. doi: 10.1073/pnas.1303445110. Epub 2013 Jul 8.

6.

OLego: fast and sensitive mapping of spliced mRNA-Seq reads using small seeds.

Wu J, Anczuków O, Krainer AR, Zhang MQ, Zhang C.

Nucleic Acids Res. 2013 May 1;41(10):5149-63. doi: 10.1093/nar/gkt216. Epub 2013 Apr 9.

7.

BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy.

Anczuków O, Buisson M, Léoné M, Coutanson C, Lasset C, Calender A, Sinilnikova OM, Mazoyer S.

Clin Cancer Res. 2012 Sep 15;18(18):4903-9. doi: 10.1158/1078-0432.CCR-12-1100. Epub 2012 Jul 2.

8.

Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC.

Das S, Anczuków O, Akerman M, Krainer AR.

Cell Rep. 2012 Feb 23;1(2):110-7.

9.

The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation.

Anczuków O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, Muthuswamy SK, Krainer AR.

Nat Struct Mol Biol. 2012 Jan 15;19(2):220-8. doi: 10.1038/nsmb.2207.

10.

Comparison of nonsense-mediated mRNA decay efficiency in various murine tissues.

Zetoune AB, Fontanière S, Magnin D, Anczuków O, Buisson M, Zhang CX, Mazoyer S.

BMC Genet. 2008 Dec 5;9:83. doi: 10.1186/1471-2156-9-83.

11.

Unclassified variants identified in BRCA1 exon 11: Consequences on splicing.

Anczuków O, Buisson M, Salles MJ, Triboulet S, Longy M, Lidereau R, Sinilnikova OM, Mazoyer S.

Genes Chromosomes Cancer. 2008 May;47(5):418-26. doi: 10.1002/gcc.20546.

PMID:
18273839
12.

Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins?

Anczuków O, Ware MD, Buisson M, Zetoune AB, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S.

Hum Mutat. 2008 Jan;29(1):65-73.

PMID:
17694537
13.

The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon.

Buisson M, Anczuków O, Zetoune AB, Ware MD, Mazoyer S.

Hum Mutat. 2006 Oct;27(10):1024-9.

PMID:
16941470
14.

Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility.

Sinilnikova OM, Ginolhac SM, Magnard C, Léoné M, Anczukow O, Hughes D, Moreau K, Thompson D, Coutanson C, Hall J, Romestaing P, Gérard JP, Bonadona V, Lasset C, Goldgar DE, Joulin V, Venezia ND, Lenoir GM.

Carcinogenesis. 2004 Dec;25(12):2417-24. Epub 2004 Aug 27.

PMID:
15333468

Supplemental Content

Loading ...
Support Center